



ABN 53 075 582 740

ASX ANNOUNCEMENT

31 January 2018

Quarterly Cashflow Report

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today released its Appendix 4C - Quarterly Cashflow Report.

Bionomics has continued to progress its development pipeline of innovative therapies during the quarter and to progress its business objectives.

Recent BNC210 presentations have highlighted the ongoing Phase 2 trial of BNC210 in patients with Post-Traumatic Stress Disorder (PTSD) and data from the positive Phase 2 trial in patients with Generalised Anxiety Disorder (GAD), supporting its potential as a therapy for anxiety disorders, conditions with co-morbid anxiety and stress and trauma related disorders.

- On 13 December 2017, Bionomics was featured on Channel 9 News which highlighted the unmet needs of PTSD sufferers and Bionomics' BNC210 which is being developed to treat this devastating condition suffered by as many as 10% of Australia's population. Video of the news story can be found at <http://www.bionomics.com.au/investors/media>.
- On 7 January 2018, Bionomics presented a corporate overview at the Neuroscience Innovation Forum in San Francisco. Dr Deborah Rathjen, CEO of Bionomics also participated in a panel discussion, "New Approaches to Neuropsychiatry and Pain Management".

Whilst BNC210, Bionomics' proprietary ionX drug discovery platform and our important relationship with Merck & Co., (known as MSD outside the US and Canada) are the primary focus of the Company, Bionomics' clinical stage oncology assets continued to make progress during the quarter, with completion of recruitment of the BNC101 Phase I clinical trial in colon cancer patients.

- On 31 October 2017 initial, positive data from the BNC101 Phase 1 trial was reported. The data is highly supportive of our on-going out-licensing effort providing confirmation of the recommended Phase 2 dose level, the safety and tolerability of BNC101 and indications of target engagement in patient's tumours.
- Bionomics is pleased with progress in the formal process to monetise its oncology assets taking the opportunity to meet with a number of potential partners during Biotech Showcase in San Francisco, 8-10 January 2018.

Bionomics is in a strong position to fund its development programs.

- Cash balance at 31 December 2017 was \$32.021m (30 September 2017: \$38.111m) with net operating cash expended during the quarter ended 31 December 2017 of \$6.209m (30 September 2017: \$3.927m).
- In addition, Bionomics received an R&D Tax Incentive refund of \$6.788m in January 2018, giving a current cash position of approximately \$37.8m.

- Cash receipts for the period included receipts from customers totalling \$1.683m for the current quarter (30 September 2017: \$1.755m) which were lower due to timing of receipts.
- Cash outflow reflected continued investment in the ongoing Phase 2 clinical trial of BNC210 in PTSD and the BNC101 Phase 1 clinical trial in patients with metastatic colon cancer.

Whilst section 9 of the Appendix 4C shows the estimated cash outflows for the next quarter, no estimated cash inflows are provided. The estimated cash outflows are reliant on the timing of various activities, including clinical trials, being conducted by Bionomics.

Upcoming Milestones.

- BNC210 Phase 2 PTSD clinical trial enrolment is ongoing and is expected to be completed in quarter 1, CY2018. Data from the clinical trial are anticipated in the second half of CY2018. Details of the trial can be found at its dedicated website <https://restorerresearchstudy.com>.
- In parallel, Bionomics continues to progress potential partnership discussions and the monetisation of non-core assets.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Ltd.

Deborah Rathjen
CEO & Managing Director
+61 8 8354 6100
drathjen@bionomics.com.au

Steven Lydeamore
CFO
+61 8 8354 6100
slydeamore@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates targeting ion channels. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanised monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Bionomics Limited

ABN

53 075 582 740

Quarter ended ("current quarter")

31 December 2017

Consolidated statement of cash flows		Current quarter	Year to date (6 months)
		\$A'000	\$A'000
1	Cash flows from operating activities		
1.1	Receipts from customers	1,683	3,438
1.2	Payments for		
	(a) research and development	(6,094)	(10,645)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	(74)	(157)
	(e) staff costs	(560)	(1,110)
	(f) administration and corporate costs	(535)	(1,069)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	83	273
1.5	Interest and other costs of finance paid	(712)	(1,132)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(6,209)	(10,402)
2	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows	Current quarter	Year to date (6 months)
	\$A'000	\$A'000
3 Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	138	276
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	(627)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	138	(351)

4 Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	38,111	42,875
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(6,209)	(10,402)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	138	(351)
4.5 Effect of movement in exchange rates on cash held	(19)	(101)
4.6 Cash and cash equivalents at end of quarter	32,021	32,021

5 Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter	Previous quarter
	\$A'000	\$A'000
5.1 Bank balances	16,789	42,875
5.2 Call deposits	15,232	-
5.3 Bank overdrafts		
5.4 Other (provide details)		
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	32,021	42,875

6 Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter
\$A'000
231
-

Remuneration paid to Chief Executive Officer/Managing Director and Non-Executive Directors

7 Payments to related entities of the entity and their associates

Current quarter
\$A'000

7.1 Aggregate amount of payments to these parties included in item 1.2

7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

--

8 Financing facilities available

Add notes as necessary for an understanding of the position

8.1 Loan facilities

8.2 Credit standby arrangements

8.3 Other (please specify)

Total facility amount at quarter end	Amount drawn at quarter end
\$A'000	\$A'000
20,126	20,126

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

Silicon Valley Bank US\$15m, interest 8.15%, secured by substantially all of the Group's assets, other than intellectual property.

9 Estimated cash outflows for next quarter

\$A'000

9.1 Research and development	(5,782)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	(39)
9.5 Staff costs	(544)
9.6 Administration and corporate costs	(768)
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	(7,133)

**10 Acquisitions and disposals of business
(items 2.1(b) and 2.2(b) above)**

Acquisitions

Disposals

10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:
(Director/~~Company secretary~~)

Date: 31/01/2018

Print name: Deborah Rathjen

Notes

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.